NEW YORK (GenomeWeb) — HiberGene Diagnostics said today that it has secured a non-exclusive license to use Eiken Chemical's loop-mediated isothermal amplification (LAMP) technology.
Specifically, Dublin-based HiberGene gains the rights to develop, manufacture, and market diagnostic products for human infectious diseases using LAMP in exchange for an undisclosed license fee and royalty payments.
HiberGene used the LAMP technology to develop its first two products, molecular tests for meningitis and Group B Streptococcus. Both tests are highly accurate and rapid, producing positive results in less than 10 minutes, which makes them ideal for use in a range of clinical and patient care environments.
"With this license now secured, we can begin manufacturing and marketing our meningitis and Group B Streptococcus products while also developing a range of other tests for human infectious diseases," HiberGene Executive Chairman Brendan Farrell said in a statement.